The Association Between Azathioprine Genetic Polymorphisms, Clinical Efficacy and Adverse Drug Reactions Among Egyptian Patients with Autoimmune Diseases

被引:1
作者
Abuelsoud, Nermeen [1 ,2 ]
Fayed, Hala [3 ]
Elkateeb, Engy [4 ]
机构
[1] British Univ Egypt, Fac Pharm, Dept Clin Pharm Practice, Cairo, Egypt
[2] Egyptian Russian Univ, Fac Pharm, Dept Pharm Practice Clin Pharm, Cairo, Egypt
[3] Cairo Univ, Kasr Alaini Univ Hosp, Fac Med, Dept Rheumatol & Rehabil, Cairo, Egypt
[4] Cairo Univ, Kasr Alaini Univ Hosp, Fac Med, Dept Chem & Clin Pathol, Cairo, Egypt
关键词
azathioprine; genetic polymorphisms; autoimmune diseases; Egyptian patients; THIOPURINE METHYLTRANSFERASE GENOTYPE; IMPLEMENTATION CONSORTIUM GUIDELINES; CROHNS-DISEASE; ALLELES; TPMT; PHARMACOGENETICS; MERCAPTOPURINE; INHERITANCE; PHARMACOLOGY; FREQUENCIES;
D O I
10.2147/PGPM.S285033
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: The study aimed to detect the frequencies of allelic variants (TPMT*3A, TPMT*3C, and TPMT*3G) in the TPMT genes in the Egyptian population and assess the association between TPMT polymorphisms and azathioprine (AZA)-clinical efficacy and adverse drug reactions among Egyptian patients with autoimmune diseases. Design: A prospective, observational single-center clinical trial. Setting: Rheumatology and Rehabilitation Department, Kasr Alainy University Hospital, Faculty of Medicine, Cairo University. Patients: Patients attending Kasr Alainy Rheumatology Outpatient Clinic between December 1, 2017 and June 30, 2019 were included in the study after signing a consent form. TPMT genetic polymorphisms were detected for all patients, and the association between polymorphisms presence and azathioprine's clinical efficacy and adverse drug reactions were determined. Results: A total of 150 patients with a mean age of 35.85 years were enrolled in this study. About 72% of patients were heterozygous in the TPMT*3 G460A and TPMT*3 A719G mutant alleles and 81% were wild type in the TPMT*2 G238C mutant allele. Abnormal liver function tests were detected in 42% of patients. Myelosuppression was presented as anemia which was detected in 63% of patients, leucopenia in 51%, and thrombocytopenia in 25% of patients. AZA clinical failure has occurred in 50% of patients where AZA was discontinued or shifted to another drug which occurred in 45% of patients. Myelosuppression rates were higher in homozygous patients in the three mutant alleles, but statistically significant in TPMT*2 G238C while not statistically significant in TPMT*3 G460A and TPMT*3 A719G. Females had a higher risk of immunosuppression than males (p-value 0.031). Conclusion: The study provided an overview of the genomic variations in the Egyptian population. Routine TPMT genotyping prior to the initiation of AZA therapy should be considered.
引用
收藏
页码:179 / 187
页数:9
相关论文
共 34 条
  • [21] THE CLINICAL-PHARMACOLOGY OF 6-MERCAPTOPURINE
    LENNARD, L
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (04) : 329 - 339
  • [22] TPMT in the treatment of Crohn's disease with azathioprine
    Lennard, L
    [J]. GUT, 2002, 51 (02) : 143 - 146
  • [23] The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics
    McLeod, HL
    Siva, C
    [J]. PHARMACOGENOMICS, 2002, 3 (01) : 89 - 98
  • [24] Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy:: Possible role of concomitant methotrexate
    Pettersson, B
    Almer, S
    Albertioni, F
    Söderhäll, S
    Peterson, C
    [J]. THERAPEUTIC DRUG MONITORING, 2002, 24 (03) : 351 - 358
  • [25] Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update
    Relling, M. V.
    Gardner, E. E.
    Sandborn, W. J.
    Schmiegelow, K.
    Pui, C-H
    Yee, S. W.
    Stein, C. M.
    Carrillo, M.
    Evans, W. E.
    Hicks, J. K.
    Schwab, M.
    Klein, T. E.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (04) : 324 - 325
  • [26] Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing
    Relling, M. V.
    Gardner, E. E.
    Sandborn, W. J.
    Schmiegelow, K.
    Pui, C-H
    Yee, S. W.
    Stein, C. M.
    Carrillo, M.
    Evans, W. E.
    Klein, T. E.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (03) : 387 - 391
  • [27] Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants
    Schaeffeler, E
    Fischer, C
    Brockmeier, D
    Wernet, D
    Moerike, K
    Eichelbaum, M
    Zanger, UM
    Schwab, M
    [J]. PHARMACOGENETICS, 2004, 14 (07): : 407 - 417
  • [28] Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry
    Schaeffeler, Elke
    Jaeger, Simon U.
    Klumpp, Verena
    Yang, Jun J.
    Igel, Svitlana
    Hinze, Laura
    Stanulla, Martin
    Schwab, Matthias
    [J]. GENETICS IN MEDICINE, 2019, 21 (09) : 2145 - 2150
  • [29] Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia
    Schmiegelow, K.
    Forestier, E.
    Hellebostad, M.
    Heyman, M.
    Kristinsson, J.
    Soderhall, S.
    Taskinen, M.
    [J]. LEUKEMIA, 2010, 24 (02) : 345 - 354
  • [30] AUTOIMMUNE-DISEASES - THE FAILURE OF SELF TOLERANCE
    SINHA, AA
    LOPEZ, MT
    MCDEVITT, HO
    [J]. SCIENCE, 1990, 248 (4961) : 1380 - 1388